Browsing Molecular Pathology by author "Buus, Richard"
Now showing items 1-20 of 20
-
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ... -
Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
Klintman, M; Buus, R; Cheang, MCU; Sheri, A; Smith, IE; et al. (AMER ASSOC CANCER RESEARCH, 2016-05-15)PURPOSE: The primary aim was to derive evidence for or against the clinical importance of several biologic processes in patients treated with neoadjuvant chemotherapy (NAC) by assessing expression of selected genes with ... -
Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (SPRINGER, 2020-04-01) -
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus, R; Sestak, I; Kronenwett, R; Denkert, C; Dubsky, P; et al. (OXFORD UNIV PRESS INC, 2016-11-01)BACKGROUND: Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer helps decisions on using adjuvant chemotherapy. ... -
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak, I; Buus, R; Cuzick, J; Dubsky, P; Kronenwett, R; et al. (2018-04)Importance:Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. Objective:To conduct a ... -
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak, I; Buus, R; Cuzick, J; Dubsky, P; Kronenwett, R; et al. (AMER MEDICAL ASSOC, 2018-02-15)IMPORTANCE: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. OBJECTIVE: To conduct a ... -
Comprehensive comparison of the performance of six prognostic signatures for oestrogen receptor positive breast cancer receiving endocrine treatment
Sestak, I; Buus, R; Cuzick, J; Dubsky, P; Kronenwett, R; et al. -
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.
Buus, R; Szijgyarto, Z; Schuster, EF; Xiao, H; Haynes, BP; et al. (NATURE RESEARCH, 2021-02-12)Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with ... -
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal, MF; Haynes, BP; Schuster, E; Yeo, B; Afentakis, M; et al. (2019-12)PURPOSE:To investigate the presence of ESR1 mutations in primary estrogen-receptor-positive (ER+) breast cancer treated with extended (>4 weeks) neoadjuvant (presurgical) aromatase inhibitor (NAI) therapy and to identify ... -
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal, MF; Haynes, BP; Schuster, E; Yeo, B; Afentakis, M; et al. (AMER ASSOC CANCER RESEARCH, 2019-12-15)PURPOSE: To investigate the presence of ESR1 mutations in primary estrogen-receptor-positive (ER+) breast cancer treated with extended (>4 weeks) neoadjuvant (presurgical) aromatase inhibitor (NAI) therapy and to identify ... -
Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting
Dowsett, M; Ferreira Leal, M; Haynes, B; Schuster, E; Yeo, B; et al. -
Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study.
Lawler, K; Papouli, E; Naceur-Lombardelli, C; Mera, A; Ougham, K; et al. (BMC, 2017-10-13)BACKGROUND: Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are ... -
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment.
Schuster, EF; Gellert, P; Segal, CV; López-Knowles, E; Buus, R; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-01)PURPOSE: Although aromatase inhibitor (AI) treatment is effective in estrogen receptor-positive postmenopausal breast cancer, resistance is common and incompletely explained. Genomic instability, as measured by somatic ... -
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Haynes, BP; Ginsburg, O; Gao, Q; Folkerd, E; Afentakis, M; et al. (NATURE PUBLISHING GROUP, 2019-11-15)The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. ... -
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; et al. (SPRINGERNATURE, 2019-01-22)BACKGROUND: Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ... -
Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
Buus, R; Sestak, I; Kronenwett, R; Ferree, S; Schnabel, CA; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-01-10)PURPOSE: The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of ... -
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; et al. (BMC, 2018-09-04)BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ... -
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Sestak, I; Filipits, M; Buus, R; Rudas, M; Balic, M; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-01)PURPOSE: Invasive lobular carcinoma (ILC) accounts for approximately 5%-15% of all invasive breast cancer cases. Most of the correlations between multigene assays and patient outcome were derived from studies based on ... -
Real-time ex vivo perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study.
Barrow-McGee, R; Procter, J; Owen, J; Woodman, N; Lombardelli, C; et al. (WILEY, 2020-03-01)Understanding how breast cancer (BC) grows in axillary lymph nodes (ALNs), and refining how therapies might halt that process, is clinically important. However, modelling the complex ALN microenvironment is difficult, and ... -
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Buus, R; Sestak, I; Barron, S; Loughman, T; Fender, B; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1, and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in estrogen receptor (ER)-positive/HER2-negative ...